Latest news
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials? - CancerNetworkCancerNetwork · Thu, 06 Aug 2026 19:09:04 GMTThe Long-Term Infection Risk: How Pharmacists Are Approaching Prophylaxis and Monitoring in Bispecific Myeloma Care - Pharmacy TimesPharmacy Times · Wed, 05 Aug 2026 12:30:21 GMTTeclistamab/Talquetamab Hits Record Low HR in Multiple Myeloma - CancerNetworkCancerNetwork · Sun, 02 Aug 2026 16:04:35 GMT